Emmanuel S. Antonarakis, M.D.

Cited by

	All	Since 2020
Citations	36099	23230
h-index	85	69
i10-index	340	275

6000

3000

1500

4500

201120122013201420152016201720182019202020212022202320242025142 265 379 642 1231 1900 2154 2505 3079 3941 5007 4666 4380 4695 467

Public access

View all

280 articles

13 articles

available

not available

Based on funding mandates

Co-authors

Mario EisenbergerProfessor of Oncology,Johns Hopkins UniversityVerified email at jhmi.edu
samuel denmeadeVerified email at jhmi.edu
Jun LuoUrology, Johns Hopkins UniversityVerified email at jhmi.edu
Tamara LotanProfessor and Deputy Director for Research, Department of Pathology, Johns Hopkins UniversityVerified email at jhmi.edu
Angelo M. De Marzo M.D., Ph.D.Professor of Pathology, Urology and Oncology, The Johns Hopkins University School of MedicineVerified email at jhmi.edu
William B. IsaacsProfessor of Urology and Oncology, Brady Urological Inst, Johns Hopkins Univ, School of MedicineVerified email at jhmi.edu
Michael SchweizerAssociate Professor, University of WashingtonVerified email at uw.edu
Johann de BonoInstitute of Cancer ResearchVerified email at icr.ac.uk
Kenneth PientaProfessor of Urology, Oncology, Pharmacology and Molecular Sciences, Johns Hopkins UniversityVerified email at jhmi.edu
Catherine Handy MarshallAssociate Professor, Johns Hopkins School of MedicineVerified email at jhmi.edu
Phuoc T. Tran, MD, PhDUniversity of Maryland, Dept. of Radiation OncologyVerified email at umm.edu
Pedro Isaacsson VelhoSidney Kimmel Comprehensive Cancer Center - Johns Hopkins Hospital and Hospital Moinhos de Vento.Verified email at jhmi.edu
Andrew J. ArmstrongProfessor, Duke UniversityVerified email at duke.edu
john isaacsProfessor of OncologyVerified email at jhmi.edu
Charles G. DrakeImmunologyVerified email at jhmi.edu
Evan YuVerified email at u.washington.edu
Edward M Schaeffer, MD PhDNorthwestern UniversityVerified email at northwestern.edu
Heather H. Cheng, MD, PhDProfessor of Medicine, Division of Hematology and Oncology, University of WashingtonVerified email at uw.edu
Michael J. MorrisMemorial Sloan-Kettering Cancer CenterVerified email at mskcc.org
James EshlemanProfessor of Patholgy, Oncology, Johns Hopkins UniversityVerified email at jhmi.edu

Emmanuel S. Antonarakis, M.D.

Clark Endowed Professor of Medicine, University of Minnesota

Verified email at umn.edu - Homepage

Prostate cancer Cancer genetics


Title Sort by citations Sort by year Sort by title	Cited by Cited by	Year
Detection of circulating tumor DNA in early-and late-stage human malignancies C Bettegowda, M Sausen, RJ Leary, I Kinde, Y Wang, N Agrawal, ... Science translational medicine 6 (224), 224ra24-224ra24, 2014	5097	2014
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer ES Antonarakis, C Lu, H Wang, B Luber, M Nakazawa, JC Roeser, ... New England Journal of Medicine 371 (11), 1028-1038, 2014	2970	2014
Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3 HI Scher, MJ Morris, WM Stadler, C Higano, E Basch, K Fizazi, ... Journal of Clinical Oncology 34 (12), 1402-1418, 2016	1482	2016
Prostate cancer, version 2.2019, NCCN clinical practice guidelines in oncology JL Mohler, ES Antonarakis, AJ Armstrong, AV D’Amico, BJ Davis, T Dorff, ... Journal of the National Comprehensive Cancer Network 17 (5), 479-505, 2019	1344	2019
Outcomes of observation vs stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE phase 2 randomized clinical trial R Phillips, WY Shi, M Deek, N Radwan, SJ Lim, ES Antonarakis, SP Rowe, ... JAMA oncology 6 (5), 650-659, 2020	986	2020
Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, M Nakazawa, R Nadal, ... JAMA oncology 1 (5), 582-591, 2015	710	2015
Ruthenium-based chemotherapeutics: are they ready for prime time? ES Antonarakis, A Emadi Cancer chemotherapy and pharmacology 66, 1-9, 2010	663	2010
Pembrolizumab for treatment-refractory metastatic castration-resistant prostate cancer: multicohort, open-label phase II KEYNOTE-199 study ES Antonarakis, JM Piulats, M Gross-Goupil, J Goh, K Ojamaa, ... Journal of Clinical Oncology 38 (5), 395-405, 2020	646	2020
Initial Evaluation of [¹⁸F]DCFPyL for Prostate-Specific Membrane Antigen (PSMA)-Targeted PET Imaging of Prostate Cancer Z Szabo, E Mena, SP Rowe, D Plyku, R Nidal, MA Eisenberger, ... Molecular imaging and biology 17, 565-574, 2015	513	2015
Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with … ES Antonarakis, C Lu, B Luber, H Wang, Y Chen, Y Zhu, JL Silberstein, ... Journal of Clinical Oncology 35 (19), 2149-2156, 2017	477	2017
Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology P Nuhn, JS De Bono, K Fizazi, SJ Freedland, M Grilli, PW Kantoff, ... European urology 75 (1), 88-99, 2019	447	2019
TMPRSS2 and COVID-19: Serendipity or Opportunity for Intervention? KH Stopsack, LA Mucci, ES Antonarakis, PS Nelson, PW Kantoff Cancer discovery 10 (6), 779-782, 2020	409	2020
NCCN guidelines insights: Prostate cancer, version 1.2021: Featured updates to the NCCN guidelines E Schaeffer, S Srinivas, ES Antonarakis, AJ Armstrong, JE Bekelman, ... Journal of the National Comprehensive Cancer Network 19 (2), 134-143, 2021	384	2021
Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study AJ Armstrong, S Halabi, J Luo, DM Nanus, P Giannakakou, ... Journal of Clinical Oncology 37 (13), 1120-1129, 2019	339	2019
The natural history of metastatic progression in men with prostate‐specific antigen recurrence after radical prostatectomy: long‐term follow‐up ES Antonarakis, Z Feng, BJ Trock, EB Humphreys, MA Carducci, ... BJU international 109 (1), 32-39, 2012	323	2012
Cabazitaxel: a novel second-line treatment for metastatic castration-resistant prostate cancer CJ Paller, ES Antonarakis Drug design, development and therapy, 117-124, 2011	322	2011
PSMA-Based [¹⁸F]DCFPyL PET/CT Is Superior to Conventional Imaging for Lesion Detection in Patients with Metastatic Prostate Cancer SP Rowe, KJ Macura, E Mena, AL Blackford, R Nadal, ES Antonarakis, ... Molecular imaging and biology 18, 411-419, 2016	274	2016
Effect of bipolar androgen therapy for asymptomatic men with castration-resistant prostate cancer: results from a pilot clinical study MT Schweizer, ES Antonarakis, H Wang, AS Ajiboye, A Spitz, H Cao, ... Science translational medicine 7 (269), 269ra2-269ra2, 2015	274	2015
Management of biochemically recurrent prostate cancer after local therapy: evolving standards of care and new directions CJ Paller, ES Antonarakis Clinical advances in hematology & oncology: H&O 11 (1), 14, 2013	258	2013
Targeting androgen receptor and DNA repair in metastatic castration-resistant prostate cancer: results from NCI 9012 M Hussain, S Daignault-Newton, PW Twardowski, C Albany, MN Stein, ... Journal of Clinical Oncology 36 (10), 991-999, 2018	222	2018

The system can't perform the operation now. Try again later.

Articles 1–20

Citations per year

Duplicate citations

Merged citations

Add co-authorsCo-authors

Follow

Cited by

Co-authors